Protective effect of purinergic agonist ATPγS against acute lung injury

Keyphrases

• Protective Effect 100%
• Acute Lung Injury 100%
• Purinergic Agonist 100%
• Acute Respiratory Distress Syndrome 50%
• Cardiovascular Disease 16%
• Murine Model 16%
• Endothelial Cells 16%
• Therapeutic Potential 16%
• Lung Tissue 16%
• Cell Signaling 16%
• Lipopolysaccharide 16%
• Cell Surface 16%
• ATP Analogues 16%
• Signaling Molecules 16%
• High Morbidity 16%
• Biological Effects 16%
• Targeted Therapy 16%
• Inflammatory Response 16%
• High Mortality 16%
• Pulmonary Disease 16%
• Protective Behavior 16%
• Endothelium 16%
• Pulmonary Edema 16%
• Cell Culture Model 16%
• Complex Cell 16%
• Intratracheal Administration 16%
• Cell-cell Junctions 16%
• Acute Respiratory Failure 16%
• Beneficial Effects 16%
• Pulmonary Microvascular Endothelial Cells (PMVECs) 16%
• Induced Endothelial Cells 16%
• Adenosine 16%
• Endothelial Barrier 16%
• Bronchoalveolar Lavage 16%
• Albumin 16%
• Pyrimidine 16%
• Neutrophil Infiltration 16%
• Neutrophil Extravasation 16%
• Pulmonary Endothelium 16%
• Blood Concentration 16%
• Evans Blue 16%
• Lipopolysaccharide Endotoxin 16%
• Purinergic Receptors 16%
• Edema Formation 16%
• Lung Fluid Balance 16%
• Barrier Enhancement 16%
• Purinoreceptors 16%
• P2Y Receptors 16%
• Extracellular Purines 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Lung Injury 100%
• Purinergic Receptor Stimulating Agent 100%
• Adult Respiratory Distress Syndrome 50%
• Adenosine Triphosphate 50%
• Lipopolysaccharide 33%
• Anti-Inflammatory Drug 16%
• Cell Culture 16%
• Pyrimidine Derivative 16%
• Lung Disease 16%
• Lung Edema 16%
• Acute Respiratory Failure 16%
• Endotoxin 16%
• Purine Derivative 16%
• Evans Blue 16%
• Purinergic Receptor Blocking Agent 16%
• Purinergic P2Y Receptor 16%
• Inflammation 16%
• Adenosine Diphosphate 16%
• Uridine Triphosphate 16%
• Adenosine 16%
• Extravasation 16%
• Uridine Diphosphate 16%
• Purinergic Receptor 16%
• Cardiovascular Disease 16%